Haemonetics [HAE] vs Masimo [MASI] Detailed Stock Comparison
Haemonetics
NYSE
Loading...
Masimo
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Haemonetics wins in 13 metrics, Masimo wins in 6 metrics, with 0 ties. Haemonetics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Haemonetics | Masimo | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.68 | 129.16 | Haemonetics |
| Price-to-Book Ratio | 2.98 | 7.28 | Haemonetics |
| Debt-to-Equity Ratio | 138.87 | 61.58 | Masimo |
| PEG Ratio | -2.74 | 0.60 | Haemonetics |
| EV/EBITDA | 9.63 | 52.55 | Haemonetics |
| Profit Margin (TTM) | 12.14% | -21.32% | Haemonetics |
| Operating Margin (TTM) | 20.21% | 17.12% | Haemonetics |
| EBITDA Margin (TTM) | 20.21% | 17.12% | Haemonetics |
| Return on Equity | 18.27% | -22.37% | Haemonetics |
| Return on Assets (TTM) | 6.52% | 1.84% | Haemonetics |
| Free Cash Flow (TTM) | $142.45M | $145.30M | Masimo |
| 1-Year Return | -27.84% | 18.88% | Masimo |
| Price-to-Sales Ratio (TTM) | 1.95 | 3.52 | Haemonetics |
| Enterprise Value | $3.56B | $8.08B | Masimo |
| EV/Revenue Ratio | 2.64 | 3.75 | Haemonetics |
| Gross Profit Margin (TTM) | 59.82% | 62.90% | Masimo |
| Revenue per Share (TTM) | $27 | $40 | Masimo |
| Earnings per Share (Diluted) | $3.27 | $-5.09 | Haemonetics |
| Beta (Stock Volatility) | 0.40 | 1.21 | Haemonetics |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Haemonetics vs Masimo Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Haemonetics | 0.37% | -3.25% | -27.80% | -19.60% | -16.73% | -30.43% |
| Masimo | -0.88% | -6.00% | -12.10% | -11.00% | -25.99% | -17.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Haemonetics | -27.84% | -26.04% | -39.08% | 51.88% | 97.11% | 146.56% |
| Masimo | 18.88% | -3.16% | -34.63% | 252.18% | 469.78% | 597.85% |
Performance & Financial Health Analysis: Haemonetics vs Masimo
| Metric | HAE | MASI |
|---|---|---|
| Market Information | ||
| Market Cap | $3.27B | $10.28B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 961,710 | 631,980 |
| 90 Day Avg. Volume | 1,053,737 | 780,640 |
| Last Close | $54.54 | $139.71 |
| 52 Week Range | $50.68 - $94.99 | $107.98 - $194.88 |
| % from 52W High | -42.58% | -28.31% |
| All-Time High | $142.11 (Feb 08, 2021) | $305.21 (Nov 15, 2021) |
| % from All-Time High | -61.62% | -54.22% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.08% |
| Quarterly Earnings Growth | -0.11% | 2.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | -0.21% |
| Operating Margin (TTM) | 0.20% | 0.17% |
| Return on Equity (TTM) | 0.18% | -0.22% |
| Debt to Equity (MRQ) | 138.87 | 61.58 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $18.32 | $19.20 |
| Cash per Share (MRQ) | $6.10 | $2.75 |
| Operating Cash Flow (TTM) | $226.54M | $176.60M |
| Levered Free Cash Flow (TTM) | $233.10M | $92.86M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Haemonetics vs Masimo
| Metric | HAE | MASI |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.68 | 129.16 |
| Forward P/E | 10.21 | 30.11 |
| PEG Ratio | -2.74 | 0.60 |
| Price to Sales (TTM) | 1.95 | 3.52 |
| Price to Book (MRQ) | 2.98 | 7.28 |
| Market Capitalization | ||
| Market Capitalization | $3.27B | $10.28B |
| Enterprise Value | $3.56B | $8.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.64 | 3.75 |
| Enterprise to EBITDA | 9.63 | 52.55 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 1.21 |
| Book Value per Share (MRQ) | $18.32 | $19.20 |
Financial Statements Comparison: Haemonetics vs Masimo
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HAE | MASI |
|---|---|---|
| Revenue/Sales | $321.39M | $372.00M |
| Cost of Goods Sold | $129.15M | $138.00M |
| Gross Profit | $192.24M | $234.00M |
| Research & Development | $16.26M | $33.90M |
| Operating Income (EBIT) | $53.87M | $80.70M |
| EBITDA | $82.63M | $90.70M |
| Pre-Tax Income | $45.17M | $68.40M |
| Income Tax | $11.14M | $21.20M |
| Net Income (Profit) | $34.03M | $-170.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HAE | MASI |
|---|---|---|
| Cash & Equivalents | $306.76M | $130.80M |
| Total Current Assets | $934.98M | $1.18B |
| Total Current Liabilities | $578.11M | $546.50M |
| Long-Term Debt | $921.23M | $657.70M |
| Total Shareholders Equity | $820.84M | $946.40M |
| Retained Earnings | $352.17M | $1.32B |
| Property, Plant & Equipment | $395.15M | $183.60M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HAE | MASI |
|---|---|---|
| Operating Cash Flow | $98.50M | $62.60M |
| Capital Expenditures | $2.45M | $17.00M |
| Free Cash Flow | $100.91M | $27.00M |
| Debt Repayment | $-1.56M | $-78.80M |
| Common Stock Repurchase | $-150.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HAE | MASI |
|---|---|---|
| Shares Short | 4.37M | 4.11M |
| Short Ratio | 4.26 | 5.19 |
| Short % of Float | 0.12% | 0.11% |
| Average Daily Volume (10 Day) | 961,710 | 631,980 |
| Average Daily Volume (90 Day) | 1,053,737 | 780,640 |
| Shares Outstanding | 48.22M | 53.60M |
| Float Shares | 47.60M | 46.46M |
| % Held by Insiders | 0.01% | 0.06% |
| % Held by Institutions | 1.16% | 1.07% |
Dividend Analysis & Yield Comparison: Haemonetics vs Masimo
| Metric | HAE | MASI |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |